Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636896 · ClinicalTrials.gov registry record · NA
Effects of Modafinil on Olanzapine Weight Gain
A NA study, sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00636896 is a NA study that has completed, run by Neuropsychiatric Research Institute, Fargo, North Dakota. The registered enrollment target is 50 participants.
The verdict
NCT00636896, a NA study, has completed, sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively. Feeding lab assessments will be conducted at baseline and endpoint. Assessments of hunger/satiety, kilocalories consumed and weight will be obtained. Plasma ghrelin and PYY3-36 levels will be drawn at baseline and endpoint prior to breakfast and two hours post. Study hypothesis: The modafinil/olanzapine group will gain less weight than the olanzapine/placebo group over three weeks of drug intake.
Interventions
- DRUG Olanzapine plus modafinil
- DRUG Olanzapine plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00636896
The ClinicalTrials.gov registry entry for NCT00636896 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuropsychiatric Research Institute, Fargo, North Dakota, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine plus modafinil is the first listed.
NCT00636896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00636896 about?
NCT00636896 is a clinical study titled "Effects of Modafinil on Olanzapine Weight Gain". This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively. Feeding lab assessments will be conducted at baseline and endpoint. Assessments of hunger/satiety, kilocalories consumed and weight will ...
What is the current status of trial NCT00636896?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2006-07. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00636896?
The interventions under investigation include: Olanzapine plus modafinil (DRUG), Olanzapine plus placebo (DRUG).
Who is sponsoring clinical trial NCT00636896?
This trial is sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.